Cancer Drug Resistance: Targeting Proliferation or Programmed Cell Death

Author:

Sazonova Elena V.12,Yapryntseva Maria A.12,Pervushin Nikolay V.12,Tsvetcov Roman I.12,Zhivotovsky Boris123ORCID,Kopeina Gelina S.12

Affiliation:

1. Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia

2. Faculty of Medicine, MV Lomonosov Moscow State University, 119991 Moscow, Russia

3. Division of Toxicology, Institute of Environmental Medicine, Karolinska Institute, P.O. Box 210, 17177 Stockholm, Sweden

Abstract

The development of resistance to chemotherapy is one of the main problems for effective cancer treatment. Drug resistance may result from disturbances in two important physiological processes—cell proliferation and cell death. Importantly, both processes characterize alterations in cell metabolism, the level of which is often measured using MTT/MTS assays. To examine resistance to chemotherapy, different cancer cell lines are usually used for the in vitro modulation of developing resistance. However, after the creation of resistant cell lines, researchers often have difficulty in starting investigations of the mechanisms of insensitivity. In the first stage, researchers should address the question of whether the drug resistance results from a depression of cell proliferation or an inhibition of cell death. To simplify the choice of research strategy, we have suggested a combination of different approaches which reveal the actual mechanism. This combination includes rapid and high-throughput methods such as the MTS test, the LIVE/DEAD assay, real-time cell metabolic analysis, and Western blotting. To create chemoresistant tumor cells, we used four different cancer cell lines of various origins and utilized the most clinically relevant pulse-selection approach. Applying a set of methodological approaches, we demonstrated that three of them were more capable of modulating proliferation to avoid the cytostatic effects of anti-cancer drugs. At the same time, one of the studied cell lines developed resistance to cell death, overcoming the cytotoxic action.

Funder

Russian Science Foundation

Swedish

Stockholm

Publisher

MDPI AG

Reference57 articles.

1. Hallmarks of Cancer: New Dimensions;Hanahan;Cancer Discov.,2022

2. Hanahan, D., and Weinberg, R.A. (2017). Holland-Frei Cancer Medicine, Wiley.

3. Senescence and Cancer—Role and Therapeutic Opportunities;Schmitt;Nat. Rev. Clin. Oncol.,2022

4. Targeting Senescence as an Anticancer Therapy;Bousset;Mol. Oncol.,2022

5. Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy?;Chen;Front. Oncol.,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3